Please assess the completion status of the following clinical trial:

Trial Title: 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • HIV-1 documented infection~  * Age 18 years or older~ * HIV-1 viral load always ≤ 50 cp/mL for at least 12 months (with a minimum of 3 measures in the last 12 months, including screening)~ * CD4+ lymphocytes count \> 250/mm3, for at least 6 months~ * Treatment with a stable regimen for at least 4 months prior to screening, containing 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTI) combined with, either 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), or 1 ritonavir-boosted protease inhibitor (PI/r). The list of accepted antiretroviral drugs is limited to :~    1. NRTI : tenofovir, emtricitabine, abacavir, lamivudine~   2. PI/r : lopinavir/r, darunavir/r or atazanavir/r~   3. NNRTI : efavirenz, rilpivirine or etravirine.~ * Exclusive antiretroviral 3 drug-therapy (no 4 drug-therapy)~ * A least one genotypic resistance test available (reverse transcriptase and/or protease amino acid sequence, according to on-going antiretroviral drugs) ; on each genotypic resistance test(s) available in medical history, susceptibility to every on-going antiretroviral drugs must be demonstrated~ * Clearance of the creatinine \> 60 mL/min (MDRD)~ * ASAT and ALAT \< 3 ULN~ * Hemoglobin \> 10 g/dl~ * Platelets count \> 100 000/mm3~ * Negative pregnancy test for potential child-bearing women and mechanical contraception for sexual intercourses~ * Patient living in France and affiliated to a social security system~ * Written informed consent~Exclusion Criteria:~* • HIV-2 infection~  * HBV infection (positive HBs antigen) or isolated positive HBc antibody~ * HCV infection requiring specific treatment during the 51 weeks of the trial~ * At least one known resistance to one of on-going antiretroviral drugs~ * Exclusive antiretroviral 3 drug-therapy (no 4 drug-therapy)~ * No genotypic resistance test available~ * On-going either interferon, interleukin treatment, or every immuno- / chemo-therapy~ * Progressive opportunistic infection, on-going treatment for opportunistic infection or tuberculosis~ * Patient with irregular follow-up or with treatment adherence problems~ * Any condition (alcohol, drug abuse...) compromising treatment adherence, treatment safety, and/or study adherence~ * Progressive neurological disorders (meningitis, encephalitis, myelitis...) related to HIV infection or not~ * Medical history of severe neuropsychiatric disorder, with insufficient treatment efficacy~ * Subject under legal guardianship or incapacitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Four consecutive days on treatment and 3 days off (Type: EXPERIMENTAL): All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).